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a b s t r a c t
Insulin-loaded alginate microspheres prepared by emulsification/internal gelation were
reinforced by blending with polyanionic additive polymers and/or chitosan-coating in order
to increase the protection of insulin at simulated gastric pH and obtain a sustained release
at simulated intestinal pH. Polyanionic additive polymers blended with alginate were cellu-
lose acetate phtalate (CAP), Eudragit® L100 (EL100), sodium carboxymethylcellulose (CMC),
polyphosphate (PP), dextran sulfate (DS) and cellulose sulfate (CS). Chitosan-coating was
applied by using a one-stage procedure. The influence of additive polymers and chitosan-
coating on the size distribution ofmicrospheres, encapsulation efficiency and release profile
of insulin in simulated gastrointestinal pH conditions was studied. The mean diameter of
blended microspheres ranged from 65 to 106m and encapsulation efficiency of insulin
varied from 14 to 100%, reaching a maximum value when CS and DS were incorporated in
the alginate matrix. Insulin release, at pH 1.2, was almost prevented by the incorporation of
PP, DS and CS. When uncoated microspheres were transferred to pH 6.8, a fast dissolution
occurred, independently of the additive polymer blended with alginate, and insulin wascompletely released. Increasing the additive polymer concentration in the alginate matrix
and/or chitosan-coating the blended alginate microspheres did not promote a sustained
microspheres at pH 6.8.
extrahepatic insulin-dependent tissues. Since the principalrelease of insulin from
1. Introduction
Insulin is a therapeutically active protein of great interest for
its broad use in the treatment of diabetes mellitus. The opti-
mal method of insulin delivery should be safe and correct
the metabolic abnormalities of diabetes, and must be psycho-
logically and socially acceptable (Brange and Langkjaer, 1997).
However, in clinical therapy, insulin ismainly administeredvia
∗ Corresponding author. Tel.: +351 239 855085; fax: +351 239 855099.
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0928-0987/$ – see front matter © 2006 Elsevier B.V. All rights reserved.
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the subcutaneous routewhich is associatedwith local discom-
fort and multiple administrations. Another disadvantage is
occasional hyperinsulinaemiadue tooverdosebecause insulin
is administered in a non-physiological way, targeting mainlyorgan in glucose homeostasis is the liver this should logically
be the prime target for intervention (Arbit, 2004). Further-
more, the oral route is considered to be the most acceptable
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nd convenient route of drug administration for chronic
herapy.
One major problem associated with the oral delivery of
nsulin is its low bioavailability due to the proteolytic activity
f the acidic juice in the stomach, susceptibility to enzymatic
ttack by intestinal proteases and peptidases, poor intrin-
ic permeability across biological membranes, rapid post-
bsorptive clearance and chemical and physical instability
Sood and Panchagnula, 2001).
Several attempts have been proposed to improve oral
ioavailability, among them microencapsulation represents a
romising concept (Carino and Mathiowitz, 1999). The encap-
ulated insulin may be protected against proteolytic attack
n the physical environment of the formulation itself and
icroparticles may release the peptide at or near the cellular
embrane to optimize the driving force for passive perme-
tion. A mild encapsulation method should be adopted to
uarantee the preservation of the native protein structure dur-
ng preparation, storage and release. In order to minimize
rotein denaturation or aggregation and loss of its biologi-
al activity, the exposure to high temperatures, high shearing
r organic solvents should be avoided (van de Weert et al.,
000).
In a previous work from our group, insulin was encapsu-
ated in alginate microspheres prepared by the emulsifica-
ion/internal gelation method (Silva et al., 2006). Alginate is a
iodegradable, biocompatible, non-toxic and naturally occur-
ing polysaccharide composed of -l-guluronic (G) and -d-
annuronic (M) acids. Alginate solution forms a gel matrix, in
ild conditions, in the presence of divalent ions, such as Ca2+.
his gelation is known toariseprimarily at junctions (“egg–box
unctions”) in G–G-sequence rich chain regions (G-blocks). In
he emulsification/internal gelationmethod, alginate solution
ontaining an insoluble calcium salt is dispersed in oil to form
water/oil (w/o) emulsion and gelation is achieved by gen-
le acidification with an oil-soluble acid that causes calcium
on release. This technique proved to be appropriate to main-
ain insulin biological stability, since insulin extracted from
he microspheres induced a hypoglycemic effect following
ts subcutaneous administration to diabetic rats (Silva et al.,
006). This formulation was also evaluated in simulated gas-
rointestinal pH conditions to determine its suitability for oral
dministration. However, insulin was released before reach-
ng the intestinal pH, where absorption should occur. A high
nsulin release, near 80%,was obtained at pH1.2,whichmeans
hat alginate microspheres by themselves could not protect
nsulin from the gastric environment.
Gelmatrix of calcium alginatemicrospheres is usually very
ermeable having a low retention capacity of encapsulated
olecules due to its pH dependent solubility (Gursoy and
evik, 2000). There have been made numerous efforts to con-
rol the erosion of alginate microspheres and extend drug
elease. The most commonly investigated approach consists
n coating microspheres with polycationic polymers such as
hitosan (Anal and Stevens, 2005; Ribeiro et al., 2005) or poly-
-lysine (Cui et al., 2001; Ueng et al., 2004). Another approach
o control the drug release from alginate microspheres con-
ists in blending alginate with other polymers, such as, cellu-
osic derivatives (El-Kamel et al., 2003), acrylic polymers (Iruin
t al., 2005), pectin (Pillay et al., 2005), chitosan (Murata etal sc i ences 2 9 ( 2 0 0 6 ) 148–159 149
al., 2003), polyvinylpyrrolidone (Chan and Heng, 1998), chon-
droitin sulfate (Murata et al., 1996) or gelatine (Almeida and
Almeida, 2004). In the case of peptide drugs, such as insulin,
the prevention of insulin release at simulated gastric pH and
a sustained release at simulated intestinal pH are considered
desirable.
The purpose of thisworkwas to encapsulate insulin in algi-
nate microspheres prepared by emulsification/internal gela-
tion reinforced by blending alginate with other polymers
and/or coating microspheres with a polycation. The preserva-
tion of optimal characteristics of size distribution and encap-
sulation efficiency was a concern. Anionic polyelectrolytes
were selected as blending polymers and chitosan was chosen
as polycation. Polyanionic additive polymers were chosen for
blending with alginate, due to the fact that having the same
charge as alginate will prevent an interaction between the
two polymers, which could interfere with the microspheres
preparation by emulsification/internal gelation. Furthermore,
it has been observed that the interaction between alginate and
insulin is very important to assure a high insulin encapsu-
lation efficiency (Silva et al., 2006). The addition of another
polyanion should not interfere with this interaction and may,
on the contrary, contribute to reinforce it. The influence of for-
mulation on insulin release from microspheres was evaluated
in simulated gastrointestinal pH conditions and the retention
of insulin at gastric pH was considered critical in selecting an
optimized formulation, so that insulin could not be released
before reaching its absorption site, the small intestine. The
achievement of a sustained release at simulated intestinal
pH was also an objective, in order to reduce the potential
degradation of insulin before absorption and to profit from the
bioadhesive properties of alginate (Chickering et al., 1997) and
chitosan (Lehr et al., 1992), which may increase the residence
time in the upper small intestine.
2. Materials and methods
2.1. Materials
Sodium alginate (Algogel® 3541) was obtained from Degussa
Texturant Systems (Boulogne-Billancourt, France). This algi-
nate presented a viscosity measured with a rotational vis-
cometer (Visco Star plus, Fungilab, S.A., Barcelona, Spain) for
a 1% solution at 20 ◦C of 318mPas. Cellulose sulfate, dex-
tran sulfate, polyphosphate, sodium carboxymethylcellulose
and Eudragit® L100 were supplied by Acros Organic (Geel,
Belgium) Sigma (Steinheim, Germany), Riedel-de-Hae¨n (Stein-
heim, Germany), Akzo Nobel (Amersfoot, Netherlands) and
Rho¨m Pharma Polymers (Darmstadt, Germany), respectively.
Cellulose acetate phthalate and paraffin oil were purchased
from Vaz Pereira (Lisbon, Portugal). Low molecular weight
chitosan, having around 150kDa (supplier specification), and
sorbitan monooleate (Span® 80, HLB 4.3±1) were purchased
from Fluka Chemie GmbH (Buchs, Switzerland). Calcium car-
bonate (Setacarb® 06) was supplied by Omya (Orgon, France).
Insulin was obtained as a regular human insulin of recombi-
nant DNA origin (Actrapid® 100 IU/ml) from Novo Nordisk A/S
(Bagsvaerd, Denmark). All other chemicals used were of ana-
lytical reagent grade.
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2.2. Methods
2.2.1. Preparation of microspheres
Microspheres were prepared by emulsification/internal gela-
tion as described in a previous work (Silva et al., 2006). Briefly,
a 2% (w/v) sodium alginate solution was prepared by disso-
lution of the polymer in an insulin solution at 0.1% (w/v). In
additive polymer-blended microspheres, a polyanionic addi-
tive polymer was dissolved in the alginate solution at 0.5 or
1% (w/v). Additive polymers included cellulose acetate phtha-
late (CAP), Eudragit® L100 (EL100), sodium carboxymethylcel-
lulose (CMC), polyphosphate (PP), dextran sulfate (DS) and
cellulose sulfate (CS). Viscosity measurements of the algi-
nate:additive blends were performed using a rotational vis-
cometer (Visco Star plus, Fungilab, S.A., Barcelona, Spain),
at 22 ◦C.
A suspension of 5% (w/v) ultrafine CaCO3 was added to the
polymer solution to obtain a calcium/alginate ratio (w/w) of
7.3% and, after homogenization, the mixture was dispersed
into paraffin oil (30% internal phase ratio, v/v) containing 1%
Span® 80 by stirring at 400 rpm using an Ika-Eurostar® mixer
(Ika, Staufen, Germany) equipped with a marine impeller.
The emulsion was formed in a round-bottomed cylindrical
glass reaction vessel. After 15min of emulsification, 20ml
of paraffin oil containing glacial acetic acid was added to
the w/o emulsion to obtain an acetic acid/calcium molar
ratio of 3.5 and stirring continued to permit CaCO3 solubi-
lization. Gelled microspheres were recovered from oily phase
by using an acetate buffer at pH 4.5 (United States Phar-
macopeia [USP] XXVIII) and successively washed with this
buffer until no more oil was detected by optical microscope
observation.
Chitosan-coating was applied by using a continuous
microencapsulation procedure designated as one-stage coat-
ing (Ribeiro et al., 2005). An emulsion of 0.1% (w/v) of acetate
chitosan at pH 4.5, in paraffin oil (50/50, v/v) containing 1%
Span® 80,was added to the oily-dispersed gelledmicrospheres
and stirring was performed for 30min. Coated microspheres
were recovered as described above.
Microspheres were frozen in an ethanol bath (Benchtop
shell freezer, Freezone® model 79490, Labconco, Kansas City,
MS, USA) at −50 ◦C and freeze-dried (Lyph-lock 6 apparatus,
Labconco) at 0 ◦C for, at least, 48h.
2.2.2. Morphological and particle size analysis
An optical microscope Olympus BH2-UMA equipped with
a Cue-2 image analyser (Olympus, Tokyo, Japan) was used
to study microsphere morphology. The shape and surface
texture of microspheres was examined by scanning elec-
tron microscopy (SEM) (JEOL JSM-840®, 10 kV, Tokyo, Japan).
The samples were mounted on metal stubs, using double
sided adhesive tape, gold coated under vacuum and then
examined.
Granulometric size distribution was determined in wash-
ing media by laser diffractometry (Fraunhofer model) using a
Coulter LS130 particle analyser (Beckman Coulter Inc., Fuller-
ton, CA, USA), with a size range from 0.1 to 1000m. Parti-
cle size is expressed as volume mean diameter (m)±S.D.
values of the mean. Measurements were made in trip-
licate for each batch. Polydispersity was determined byal sc i ences 2 9 ( 2 0 0 6 ) 148–159
the SPAN factor (El-Mahdy et al., 1998) expressed as
SPAN= [D(v,90)−D(v,10)]/D(v,50), where D(v,90), D(v,10) and
D(v,50) are volume size diameters at 90, 10 and 50% of
the cumulative volume, respectively. A high value of SPAN
indicates a wide distribution in size and a high polydis-
persity.
2.2.3. Insulin content and encapsulation efficiency
To determine the insulin content, 5mg of lyophilized insulin-
loaded microspheres were accurately weighed and incubated
in 5ml of phosphate buffer at pH 7.4 (USP XXVIII), containing
0.1M ethylenediamine tetra-acetic acid (EDTA), under mag-
netic stirring (100 rpm/2h). Samples were withdrawn after
incubation and analysed for insulin content by high per-
formance liquid chromatography (HPLC). Insulin content (%,
w/w) was defined as the amount of insulin (mg) in 100mg of
microspheres. The encapsulation efficiency (%) of insulin was
calculated from the ratio between the actual insulin content
and the theoretical insulin content. Assays were performed in
triplicate.
2.2.4. In vitro release studies
A multiple stirring points plate was used for in vitro release
studies. Insulin-loaded microspheres (20mg) were placed in
20ml of hydrochloric acid buffer at pH 1.2 (USP XXVIII) and
stirred at 100 rpm. After 2h, the microspheres were trans-
ferred to 20ml of phosphate buffer at pH 6.8 (USP XXVIII)
and incubated for 4h. Two millilitre of sample was taken
at appropriate intervals from both media and insulin con-
tent was determined by HPLC. Assays were performed in
triplicate.
2.2.5. Insulin analysis
Samples withdrawn from hydrochloric acid buffer at pH 1.2
were centrifuged (13,400 rpm/10min) and the supernatant
was used for insulin analysis. Samples obtained from phos-
phate buffer at pH 6.8 were mixed with 0.2M NaOH, to raise
pH above 7.0, followed by addition of ethanol (50/50, v/v) to
precipitate alginate. After mixing, samples were centrifuged
(13,400 rpm/10min) and the supernatant was analysed to
determine insulin content.
The concentration of insulin was determined by using a
HPLC system (model HP1100 series, Hewlett Packard, Ger-
many) equipped with an autosampler (Agilent 1100 series,
Germany). A reversed-phase X-Terra C-18 column, 5m,
4.6mm×250mm (Waters, USA), with a Purospher® STAR RP-
18 precolumn, 5m, 4mm×4mm (Merck, Germany) was
employed. Mobile phase A consisted of 0.04% trifluoroacetic
acid (TFA) in water and mobile phase B was 0.04% TFA in ace-
tonitrile. A linear gradient of 30–40% B over 5min was used
with a flow rate of 1.2ml/min. Volumes of 20l were injected,
the UV detector was set at 210nm and HPLC analysis was car-
ried at 27 ◦C. A retention time of 4.5min was obtained.
2.2.6. Statistical analysis
Each value was expressed as the mean±S.D. Statistical dif-
ferences were analysed by using a one-way analysis of vari-
ance (ANOVA) followed by a Bonferroni post test. For a
value of P less than 0.05 the difference was considered
significant.
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Fig. 1 – Viscosity of alginate: additive polymer blends
before the encapsulation. ALG corresponds to the alginate
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dditive polymers were added to alginate solution at 0.5%
w/v). *P<0.01 by comparison with ALG.
. Results
.1. Influence of matrix reinforcement
lginate at 2% (w/v) was blended with another polyanion
o decrease insulin leakage from microspheres during gas-
ric passage but minimal effects on the size distribution and
ncapsulation efficiency of microspheres were desirable.
The influence on the viscosity of alginate solution at 2%
aused by the addition of the additive polymers was calcu-
ated bymeasuring the viscosity of alginate: additive polymers
lends before the emulsification step. Fig. 1 shows that the
ddition of CAP, PP and DS at 0.5% to the alginate solution at
% did not change its viscosity (P>0.05), while the addition
f EL100, CMC and CS significantly increased the viscosity of
lginate solution (P<0.01).
Microspheres obtained from pure alginate (plain micro-
pheres) showed a unimodal size distribution with a mean
iameter value of 69m and a SPAN factor of 0.8 (Table 1).
hen alginate was blended with CAP, PP and DS, no influence
as detected on the mean diameter of microspheres, but the
ddition of EL100, CMC and CS caused an increase of mean
iameter to near 100m. The SPAN factor increased with the
ean diameter of microspheres. Despite differences on mean
iameter caused by the addition of another polyanion to the
lginatematrix, a unimodal size distributionwas observed for
ll microspheres.
Table 1 – Influence of the addition of a polyanionic additive pol
microspheres
Type of additive polymer Abbreviation
– ALG
Cellulose acetate phthalate CAP
Eudragit® L100 EL100
Sodium carboxymethylcellulose CMC
Polyphosphate PP
Dextran sulfate DS
Cellulose sulfate CS
a Mean±S.D.l sc i ences 2 9 ( 2 0 0 6 ) 148–159 151
As illustrated in Fig. 2a, plain alginate microspheres were
discrete and spherical in shape and no aggregation was
observed. Tubular and star-like structures were visible on
the microspheres and could be attributed to the presence of
insulin, since they were not present in blank microspheres
preparedwithout insulin (Fig. 2b). Fig. 3 shows that all additive
polymer-blended microspheres were also composed of dis-
crete and spherical microspheres. The presence of the tubular
and star-like structures on the microspheres could be seen in
all microspheres except when EL100, DS and CS were used as
additive polymers.
To assess more relevant morphology differences among
formulations, the surface of microspheres was examined by
SEM (Fig. 4). Insulin was visible at the surface of alginate and
PP microspheres, but it could not be detected at the surface of
DS microspheres, which was in agreement with the previous
optical microphotographs.
As shown in Fig. 5, the encapsulation efficiency of insulin
was influenced by the addition of a polyanionic additive poly-
mer to alginate matrix. A high encapsulation efficiency was
obtained for plain alginate microspheres, near 86%, and the
insulin content was 4.7% (w/w), corresponding to approx-
imately 135 IU per 100mg of microspheres. Lower encap-
sulation efficiencies of insulin (P<0.001) were obtained for
microspheres reinforced with CAP and EL100, 55.6 and 13.7%,
respectively. On the other hand, DS and CMC significantly
increased the encapsulation efficiency of insulin (P<0.05)
and, in the case of DS, the encapsulation efficiency reached
near 100%.
Insulin release profile from microspheres, in gastrointesti-
nal simulated pH conditions, is plotted in Fig. 6. Plain alginate
microspheres showedan initial burst effect, at pH1.2, reaching
near 80%of total release. A fast and complete release of insulin
occurred when microspheres were transferred to phosphate
buffer at pH 6.8 due to their dissolution. Alginate at 2% was
blended with polyanions to avoid leakage of insulin at simu-
lated gastric pH. The percentage of insulin retention in micro-
spheres after a 2-h incubation at pH 1.2 differed accordingly
to the additive polymer blended with alginate. The addition
of CMC to alginate matrix did not improve insulin retention
(P>0.05), while a slight increase of the insulin retention, up
to 36%, was observed for microspheres reinforced with CAP
and EL100 (P<0.01). For PP-reinforced microspheres, only 1%
of the insulin was released at pH 1.2, while for both DS and
CS-reinforced alginate microspheres no insulin was detected
in the acidic medium.
ymer at 0.5% (w/v) on the size distribution of alginate
Mean diametera (m) SPAN factor
68.7 ± 20.8 0.82
67.4 ± 20.8 0.84
97.3 ± 38.0 0.92
108.6 ± 47.7 1.16
68.2 ± 23.3 0.89
71.3 ± 22.9 0.87
105.7 ± 42.2 1.06
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(a) aFig. 2 – Optical microphotograph of plain insulin-loaded
When additive polymer-blended alginate microspheres
were transferred to pH 6.8, a fast dissolution of microspheres
occurred for all formulations and insulin was completely
released.
3.2. Influence of chitosan-coating reinforced
microspheres
The previous results led us to study in more detail the micro-
spheres containing DS and PP because they combined high
encapsulation efficiencies with the preservation of the size
distribution characteristics of microspheres and they were
able to retain insulin release at simulated gastric pH. In order
to obtain a more sustained release of insulin from alginate
microspheres, at simulated intestinal pH, the effect of additive
polymer concentration and chitosan-coating was evaluated.
Table 2 shows the effect of the additive polymer concen-
tration and chitosan-coating on size distribution, insulin con-
tent and encapsulation efficiency of alginate microspheres.
Increasing the additive polymer concentration from 0.5 to 1%
caused no effect on mean diameter, although some tendency
Table 2 – Influence of the concentration of polyphosphate (PP) a
characteristics of alginate microspheres
Coating Type of
additive
polymer
Additive polymer
concentration
(%, w/v)
Mean dia
(m
Uncoated
– – 68.7±
PP
0.5 68.2±
1.0 96.4±
DS
0.5 71.3±
1.0 85.4±
Coated
– – 87.6±
PP
0.5 84.7±
1.0 72.3±
DS
0.5 75.1±
1.0 95.4±
a Mean±S.D.nd blank (b) alginate microspheres (magnification 200×).
for aggregation was detected. Coated microspheres showed a
slightly higher mean diameter size and SPAN factor owing to
partially aggregation during the coating process.
No changes on the morphology of plain and additive
polymer-blended microspheres, due to the presence of chi-
tosan, were detected by optical microscopy (Fig. 7). Moreover,
the increase of polyanion concentration caused no morpho-
logical differences on microspheres.
The increase of additive polymer concentration caused a
slight decrease on insulin content ofmicrospheres, whichwas
more significant for microspheres reinforced with PP (Table 2).
Nevertheless, the increase on additive polymer concentration
corresponded to an increase on encapsulation efficiency. As
described previously, insulin encapsulation efficiency is cal-
culated from the ratio between the actual insulin content and
the theoretical insulin content. When the amount of addi-
tive polymer increases, the theoretical insulin content will
decrease, owing to the increase on the total theoretical poly-
mer mass. For the microspheres containing additive polymer
at 0.5 and 1% (w/w), the theoretical insulin contents were
4.46 and 3.74%, respectively, which gives the encapsulation
nd dextran sulfate (DS) and chitosan-coating on the
metera
)
SPAN
factor
Insulin contenta
(%, w/w)
Encapsulation
efficiencya
(%, w/w)
20.8 0.82 4.7±0.1 85.6 ± 2.3
23.3 0.89 4.2±0.1 94.2 ± 2.0
30.9 0.87 3.8±0.2 101.5 ± 5.8
22.9 0.87 4.5±0.1 101.2 ± 1.5
24.4 0.78 4.4±0.1 117.3 ± 2.0
41.7 1.24 4.5±0.2 84.6 ± 3.0
29.1 0.93 4.1±0.1 94.4 ± 3.1
25.0 0.96 3.7±0.1 102.0 ± 2.4
24.2 0.89 4.1±0.1 94.8 ± 3.0
33.9 0.97 4.0±0.1 109.1 ± 1.5
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Fig. 3 – Optical microphotograph of insulin-loaded alginate microspheres containing (a) CAP, (b) EL100, (c) CMC, (d) PP, (e) DS
o
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(
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a
or (f) CS at 0.5% (w/v) (magnification 200×).
fficiency values presented in Table 2.The increase on encap-
ulation efficiency was not significant for microspheres con-
aining PP, but for microspheres with DS was very significant
P<0.001). The attainment of encapsulation efficiencies higher
han 100%, especiallywhen the additive polymerwas added at
concentration of 1% (w/w), can be explained by a partial loss
f the additive polymer during the recovery of microspheres,which decreases the theoretical polymer mass and changes
the theoretical insulin content to values higher than the pre-
viewed.Coating the microspheres did not affect the insulin con-
tent of plain and reinforced alginate microspheres (P>0.05).
In terms of insulin encapsulation efficiency, similar results
were obtained before and after chitosan-coating for plain
154 european journal of pharmaceut ical sc i ences 2 9 ( 2 0 0 6 ) 148–159
icrosFig. 4 – Surface morphology of (a) insulin-loaded alginate m
SEM micrograph (magnification 1000×).Fig. 5 – Insulin encapsulation efficiency in alginate
microspheres (ALG) blended with a polyanionic additive
polymer at 0.5% (w/v). Assays were performed in triplicate.pheres containing (b) PP or (c) DS at 0.5% (w/v) according toFig. 6 – In vitro release profile of insulin from alginate
microspheres (ALG) blended with a polyanionic additive
polymer at 0.5% (w/v). Microspheres were incubated at pH
1.2 for 2h and then transferred to pH 6.8. The results are
the mean of three experiments±S.D.
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Fig. 7 – Optical microphotograph of (a) chitosan-coated insulin-loaded alginate microspheres containing (b) PP or (c) DS at
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Fig. 8 – In vitro release profile of insulin from uncoated and.5% (w/v) (magnification 200×).
icrospheres and microspheres reinforced with PP. For DS-
einforced microspheres a significant decrease (P<0.05) was
bserved after chitosan-coating, but insulin encapsulation
fficiencywas still higher than that obtainedwith plainmicro-
pheres (P<0.05).
Chitosan-coating did not change the release profile of
nsulin from plain and DS-reinforced microspheres in sim-
lated gastrointestinal pH conditions (Fig. 8). Interestingly,
henmicrospheres containing PP at 0.5%were coated, insulin
elease increased from 1 to 11% after 2-h incubation at pH 1.2.
t pH 6.8, coated microspheres did not dissolve and main-
ained their spherical shape; however a rapid and complete
nsulin release was obtained for all the formulations.
Furthermore, increasing the concentration of DS on micro-
pheres did not induce changes on insulin release profile, for
oth uncoated and coated microspheres. In the case of PP,
he increase on additive polymer concentration caused an
ncrease on insulin release, after acid incubation, from 1 to 8%
or uncoated microspheres, but when PP concentration was
ncreased for coated microspheres, insulin release profile was
ot considerably changed. In respect to incubation at pH 6.8,
oated microspheres containing the highest concentration of
chitosan-coated (C) microspheres reinforced with PP or DS
at different concentrations. Microspheres were incubated at
pH 1.2 for 2h and then transferred to pH 6.8. The results are
the mean of three experiments±S.D.
ut ic156 european journal of pharmace
PP succeeded to retain near 40% of insulin just after changing
the pH but then in few minutes an almost total release of the
protein was achieved as observed for all the other formula-
tions.
4. Discussion
The goal of this study was to develop insulin-loaded micro-
spheres prepared by emulsification/internal gelation capable
of retaining the protein in the matrix during the gastric pas-
sage and sustaining the insulin release at simulated intestinal
pH. Two strategies were assayed: the reinforcement of cal-
cium alginate matrix with a polyanionic additive polymer and
chitosan-coating of microspheres.
Several polyanions were studied and selected according to
their suitability to prevent insulin release at simulated gas-
tric pH and to their capacity of maintaining the size distri-
bution of microspheres and the encapsulation efficiency of
insulin. CAP and EL100 are commonly used as enteric poly-
mers. CAP is a cellulose derivative that contains 21.5–26.0% of
acetyl groups and 30.0–36.0% of phthalyl groups. The molecu-
lar weight of CAP varies from 48 to 60kDa and the viscosity at
25 ◦C is 45–90mPas. EL100 is an anionic copolymer based on
methacrylic acid and methyl methacrylate with a ratio of free
carboxyl groups to the ester groups of 1:1, soluble at pH>6. The
averagemolecular weight of EL100 is 135kDa and the viscosity
at 20 ◦C is 50–200mPas. CMC is a sodium salt of a polycar-
boxymethyl ether of cellulose, which has a typical molecular
weight of 90–700kDa and a pKa value of 4.3. Low viscosity
CMC may have a viscosity between 10 and 110mPas. PP or
sodium hexametaphosphate is a linear condensed phosphate
with an average chain length of 12 and a molecular weight of
approximately 1.3 kDa. DS is a branched glucose polymer con-
taining approximately 2.3 sulfate groups per glucosyl residue
and having a molecular weight of near 5kDa. CS is a sulfated
cellulose derivativewith a degree of substitution of 1.5–2.8 sul-
fate groups per glucosyl residue and a molecular weight of
2900kDa.
The reinforcement of alginate matrix with CAP, PP and DS
permitted the maintenance of the mean diameter of micro-
spheres. The size distribution of microspheres prepared by an
emulsification methodology is related to the internal phase
viscosity (Bahukudumbi et al., 2004) but the effect of one poly-
mer on the viscosity of another polymer depends on many
factors. In our study, following the addition of CAP, PP and
DS, no effect was observed on the viscosity of alginate solu-
tion and, consequently, differences on mean size were not
observed. In previous studies, it was observed that the addi-
tion of a cellulose derivative to alginate caused an increase
on the solution viscosity and on mean size (Chan et al., 1997),
while the viscosity of a starch solution was greatly decreased
by the addition of gums, attributed to repelling forces between
the phosphate groups on starch and the negative charges on
molecules of these gums (Shi and BeMiller, 2002). Interest-
ingly, in another study, the incorporation of Eudragit® L100
55 into alginate microspheres prepared by emulsification had
no effect on the size (Gursoy et al., 1999).
Another goal of this study was the attainment of high
insulin encapsulation efficiencies, which was achieved withal sc i ences 2 9 ( 2 0 0 6 ) 148–159
the majority of the additive polymers. The increase on insulin
encapsulation efficiency in the microspheres can have two
explanations: the incorporation of an additive polymer can
create a higher network density or an electrostatic interaction
between the protein and the polyanionsmay favour the reten-
tion of insulin in the microspheres.
Higher encapsulation efficiencies were obtained for micro-
spheres containing DS and CS, but no insulin was observed
on these microspheres by using optical microscopy. We may
suppose that the protein is located inside the microspheres
and not at its surface, revealing a different type of interaction
of these polymers with insulin or a different type of polymer
network, possibly related to its higher negative net charge.
Thismore interior location of insulin in DS- and CS-reinforced
microspheresmay be favourable for protecting insulin against
enzymatic degradation.
PP, DS and CS were the most efficient additive polymers in
avoiding insulin release in acidic medium. A higher release of
insulin was obtained for microspheres reinforced with EL100,
CAP and CMC. Eudragit® L100 and CAP, insoluble in acids but
soluble at intestinal pH, have been used as enteric polymers
and their incorporation into dipyridamole-loaded alginate gel
microspheres (1:1) (Gursoy et al., 1999) and diclofenac-loaded
calcium alginate-pectinate matrix (0.2–1:1) (Pillay et al., 2002),
respectively, did not decrease drug release from microspheres
in acidic medium. Low viscosity CMC slightly decreased the
rate of sulphaguanidine release frommicrospheres composed
of alginate:CMC (7:3) (Chan et al., 1997), possibly due to the
formation of insoluble CaCMC which formed a less permeable
barrier to drug diffusion. To our knowledge DS and PP were
never used to reinforce alginate microspheres in order to con-
trol drug release profile. CS has been used in the formation of
multicomponent polyelectrolyte systems of alginate/CS and
calcium/poly(methylene-co-guanidine) hydrochloride (Wang
et al., 1997), but this system has only been applied for the
encapsulation of cells (Bartkowiak et al., 1999; Canaple et al.,
2001; Zhang et al., 2005).
The incubation of calciumalginatemicrospheres, at pH 1.2,
causes calcium ions to be displaced from the polymer network
and the calcium alginate gel is converted to the unionized
form of alginic acid (Ostberg et al., 1994). This may lead to dis-
sociation of ionic linkages and reduction in the gel strength
that may favour insulin release by diffusion. On the other
hand, during the recovery ofmicrospheres, at pH 4.5, probably
occurs an interaction between the negatively charged alginate
and the positively charged insulin (Silva et al., 2005). However,
at pH 1.2, this interaction should be affected by the possible
alginate precipitation in the form of alginic acid and a high
insulin release results from the incubation of plain alginate
microspheres at pH 1.2.
The addition of another polyanion to alginate matrix
increases the polymer concentration which may result in a
higher network density, but the effect observed on insulin
release at pH 1.2, seemed to be mainly due to electrostatic
interactions. The dissociation constants for mannuronic and
guluronic acidmonomers of alginate are 3.38 and 3.65, respec-
tively (Draget et al., 2005). In the case of DS and CS, the sulfate
groups are considered to be permanently charged since they
are known to have a negative first pKa value and a second pKa
value of near 2. The physical mixture of alginate with DS or
i ca
spheres containing DS or PP. The similar release profile at pH
6.8 obtained for coated microspheres could be explained by
the fact that chitosan formed a high porous polyelectrolyte
complex membrane that did not act as a diffusion barrier. Inl sc i ences 2 9 ( 2 0 0 6 ) 148–159 157
fact, chitosan-coated microspheres coated were still spheri-
cal and did not dissolve after incubation at pH 6.8. Although
it was possible to prevent the disintegration of microspheres,
insulin release at this pH was still very fast. Chitosan has an
apparent pKa of 6.3 and assumes a stiff extended conforma-
tion in aqueous media of low pH due to the charge repulsion
of highly protonated amino groups, but it becomes increas-
ingly globular as pH increases (Ma et al., 2002). Therefore, at
pH6.8, the resultingpolymer shrinkagemanifests as increased
membrane pore size, resulting in a microporous membrane
(Okhamafe et al., 1996). This may account for the rapid pro-
tein elution at simulated intestinal pH.
In previous studies, chitosan-coating was able to decrease
the gel erosion (Murata et al., 1993) and allow a drug sustained
release (Polk et al., 1994; Sezer andAkbuga, 1999) fromalginate
microspheres. However, in our study, uncoated and chitosan-
coated alginatemicrospheres showed the same release profile.
These contradictory results may be related to differences in
the preparation procedures, the composition of chitosan and
the composition and structure of the alginate gels (Gaserod et
al., 1998; Shu and Zhu, 2002).
Surprisingly, in the case of PP, an increase on insulin release
at pH 1.2 was obtained when microspheres were chitosan
coated. This result could be reasonably attributed to a compe-
tition between chitosan and the positively charged insulin for
PP. This polyanion has been used to cross-link chitosan in the
preparation of microspheres due to the formation of a strong
interpolymer complex between –[P2O54−]– and –NH3+ groups
of PP and chitosan, respectively (Mi et al., 1999; Angelova and
Hunkeler, 2001). The same effect was not observed for DS, also
known to interact with chitosan (Chen et al., 2003), which can
be due to a stronger interaction between DS and insulin that
retains the protein in the formulation.
Notwithstanding, the presence of chitosan may be impor-
tant for improving insulin intestinal absorption due to its
mucoadhesive properties that prolongs the residence time of
the dosage form in the intestine. Mucoadhesive polymers are
also able to reduce the enzymatic barrier by sticking to the
mucus layer at the site of drug absorption, thereby decreas-
ing the distance between the released therapeutic peptide
from the dosage form and the absorptive tissue (Bernkop-
Schnurch, 1998). Moreover, chitosan has been described for
its capacity of enhancing absorption of various compounds
across themucosal barrier via the paracellular transport path-
way (Artursson et al., 1994; Smith et al., 2004). Chitosan-coated
alginate microspheres, in particular, have shown to increase
the paracellular permeability of Lucifer Yellow, a permeability
marker, across Caco-2 cell monolayers (Silva et al., unpub-
lished data).
In conclusion, insulin-loaded alginate microspheres’ for-
mulation was optimized in order to prevent insulin release at
gastric pH. The incorporation of DS into the alginate matrix
increased the encapsulation efficiency of insulin without
affecting the mean diameter of microspheres and prevented
insulin release at pH 1.2. The stability of themicrospheresmay
be due to an electrostatic interaction between the protein andeuropean journal of pharmaceut
CS provides both pH-sensitive (carboxylic) and permanently
charged (sulfate) groups. The presence of permanent nega-
tive charges may be responsible for interacting with insulin
(isoelectric point, pI=5.3–5.4) at acidic pH, thus preventing its
release. PP also demonstrated ability to prevent insulin release
at pH 1.2. It is known that phosphoric acid has three pKa val-
ues at 2.2, 7.2 and 12.3, but in PP the number of pKa values will
be higher accordingly to the number of phosphate units. It is
possible that at pH 1.2 there are still some negative charges for
interaction with insulin, although this interaction should be
weaker than that observed with sulfate groups. In the case of
EL100, CAP and CMC, the negative charges of these polyanions
are due to carboxylic groups and probably they behave like
alginate. Based on the above considerations it can be assumed
that the structural differences between the additive polymers
are likely to affect the interaction with insulin.
Successful oral sustained-release formulation is depen-
dent on the sequential changes of environment through the
gastrointestinal tract, as it passes from the strongly acidic (pH
1–3) to the weakly alkaline (pH 6.5–7.5) medium in the lower
part of the small intestine. After changing topH6.8, a complete
and fast dissolution ofmicrospheres occurred for all uncoated
formulationsbecause thealginic acid formedduringacid incu-
bation was converted to a soluble salt of sodium alginate.
This causes the matrix to swell and disintegrate, enabling the
complete and fast release of insulin. Moreover, the reinforce-
ment of alginate microspheres with the polyanionic additive
polymers did not improve insulin release at pH 6.8. In fact,
increasing the pH to a value higher than insulin pI causes the
reversionof the interactionwith thenegatively chargedgroups
of the additive polymers.
The best results of gastric release studies were obtained
with microspheres containing PP, DS and CS, but considering
the preservation of size distribution and maintenance of high
insulin encapsulation, DS and PPwere chosen for further stud-
ies. CS increased the mean diameter of microspheres and had
lower encapsulation efficiency than DS. These two polymers
are both composed of glucose units containing sulfate groups,
but DS is a branched chain polysaccharide of near 5kDa, while
CS is a linear polymer with near 2900kDa. The highermolecu-
lar weight of CS accounts for a higher viscosity in solution and
justifies the increase on mean size. On the other hand, the
low molecular weigh of dextran sulfate, near that of insulin
(5.8 kDa) may favour the interaction between them and con-
tribute to increase the insulin retention in microspheres.
A sustained release of insulin at pH 6.8 would also be
desirable to reduce the potential degradation of insulin before
absorption. In an attempt to achieve a sustained release of
insulin from microspheres at simulated intestinal pH, the
polyanion concentration was increased but it did not give
better results. It could be expected that a higher network den-
sity could decrease the permeability of microspheres’ matrix.
However, such effect was not observed since no suppression
of the initial release of insulin, at pH 6.8, was obtained.
Another strategy used in this study to improve insulin
release profile at pH 6.8 was chitosan-coating alginate micro-the polyanion. In respect to achieving amore sustained release
of insulin at simulated intestinal pH, neither the increase
of the additive polymer concentration, nor chitosan-coating
additive polymer-reinforced microspheres were efficient. Fur-
ut
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ther studies areneeded to achieve this target and the improved
formulation should be tested for its ability to protect insulin
from proteolytic degradation. Nevertheless, chitosan-coated
DS-reinforced microspheres may be good candidates for oral
delivery of insulin, since the presence of chitosan may pro-
mote insulin absorption through the intestinal epithelia and
this needs further confirmation by in vivo studies.
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